Page last updated: 2024-08-22

platinum and sta 9090

platinum has been researched along with sta 9090 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Addi, L; Alfano, L; Baldassarre, G; Bruzzese, F; Budillon, A; Capone, F; Costa, A; Di Gennaro, E; Iannelli, F; Lombardi, R; Milone, MR; Moccia, T; Pucci, B; Roca, MS; Sonego, M	1

Other Studies

1 other study(ies) available for platinum and sta 9090

Article	Year
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Molecular oncology, 2021, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Platinum; Proteomics; Triazoles; Xenograft Model Antitumor Assays	2021

Article

Year

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.

Molecular oncology, 2021, Volume: 15, Issue:4

Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Platinum; Proteomics; Triazoles; Xenograft Model Antitumor Assays

2021